Canandaigua National Corp’s Charles River Laboratories CRL Stock Holding History

Canandaigua National Corp’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$259K	Buy	1,187 +3	+0.3%	+$655	0.04%	215
2022 Q3	$233K	Sell	1,184 -3	-0.3%	-$648	0.04%	221
2022 Q2	$254K	Sell	1,187 -8	-0.7%	-$1.96K	0.05%	212
2022 Q1	$339K	Sell	1,195 -2	-0.2%	-$617	0.05%	209
2021 Q4	$451K	Sell	1,197 -17	-1%	-$6.61K	0.07%	191
2021 Q3	$501K	Sell	1,214 -175	-13%	-$72.7K	0.08%	174
2021 Q2	$514K	Sell	1,389 -91	-6%	-$30.4K	0.08%	170
2021 Q1	$429K	Sell	1,480 -140	-9%	-$38.9K	0.07%	180
2020 Q4	$405K	Sell	1,620 -58	-3%	-$13.8K	0.07%	180
2020 Q3	$380K	Sell	1,678 -192	-10%	-$39.8K	0.07%	180
2020 Q2	$326K	Buy	+1,870	New	+$298K	0.06%	196

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Canandaigua National Corp's CRL Position: Q4 2022 in Review

Canandaigua National Corp increased its Charles River Laboratories (CRL) stake by 0.25% in Q4 2022, buying an estimated $655 and bringing the position to 1,187 shares worth $259K. The position accounts for 0.04% of the portfolio, ranked #215.

Canandaigua National Corp first reported a position in CRL in Q2 2020 and has held it in 11 quarters since. The position peaked at $514K in Q2 2021. 627 funds tracked by Wall St. Rank hold CRL as of Q4 2022.

Canandaigua National Corp held 1,187 shares of Charles River Laboratories worth $259K as of Q4 2022.
Canandaigua National Corp bought 3 Charles River Laboratories shares in Q4 2022, an estimated $655.
Charles River Laboratories made up 0.04% of Canandaigua National Corp's portfolio in Q4 2022, its #215 holding.
Canandaigua National Corp first reported a position in Charles River Laboratories in Q2 2020 and has held it in 11 quarters since.
Canandaigua National Corp's Charles River Laboratories position peaked at $514K in Q2 2021.
627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2022.

Based on Canandaigua National Corp's 13F filing for Q4 2022, filed 25 Jan 2023.